Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03145857 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use | terminated | Phase 1 / Phase 2 | 634 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 6 | Changhai HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03211988 | Entinostat Neuroendocrine (NE) Tumor | terminated | Phase 2 | 5 | Antonio FojoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05987176 | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases(NELMAS) | terminated | Phase 2 | 1 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04579679 | Open-Label Surufatinib in European Patients With NET | terminated | Phase 2 | 78 | HutchmedINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT07012330 | Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients | terminated | Phase 2 | 111 | Erasmus Medical CenterOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT02489604 | Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors(LUNET) | terminated | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05568017 | Neoadjuvant PRRT With Y-90-DOTATOC in pNET(NeoNet) | terminated | Phase 2 | 11 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03420521 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02859064 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres | terminated | Phase 2 | 6 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04543955 | Telotristat With Lutathera in Neuroendocrine Tumors | terminated | Phase 2 | 1 | Lowell Anthony, MDOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03190213 | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma(Pembro NEC) | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03670030 | A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | terminated | Phase 2 | 5 | Robert RamirezOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT00843531 | RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 17 | University of California, San FranciscoOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT02315625 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00985946 | Study of Panobinostat in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | terminated | Phase 2 | 6 | Joel NealOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT01215578 | Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors(NET) | terminated | Phase 2 | 33 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00466856 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | terminated | Phase 2 | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials